Summary of Clarivate's Conference Call Company Overview - **Company**: Clarivate - **Key Executives**: Matti Shem Tov (CEO), Jonathan Collins (CFO) Industry and Strategic Focus - **Industry**: Information and analytics services, particularly in academic, government, and life sciences sectors - **Core Strategy**: Value Creation Plan with four pillars aimed at transforming the business model and enhancing shareholder value Key Points from the Conference Call 1. Value Creation Plan - **Pillar 1: Transition to Subscription Model** - Phasing out transactional sales in favor of subscription models - Current revenue mix: 88% subscription, aiming for 90% over time [6][4][3] - Phasing out print books and transactional e-books by June 2026 [4] - New subscription products introduced: ProQuest e-books and digital collections [5] 2. Sales Execution Improvement - **Pillar 2: Enhancing Sales Execution** - Changes implemented in sales organization leading to improved retention rates and sales momentum [8][10] - New talent acquisition, including a Senior Vice President for Sales in Life Science [9] 3. Product Innovation - **Pillar 3: Focus on Product Innovation** - Emphasis on AI integration across product lines, including GenAI and agentic AI capabilities [11][12] - Development of new products like Web of Science Research Intelligence, expected to launch in May 2026 [16][27] - AI enablement of existing products to enhance customer retention and attract new customers [13][14] 4. Portfolio Rationalization - **Pillar 4: Strategic Review of Non-Core Assets** - Ongoing review to identify non-core assets for potential divestiture to enhance shareholder value [19][20] 5. Organic Revenue Growth - **Target for Growth**: Aligning with market growth rates of 3-5% across segments [21][22] - **Segments**: Academic & Government (A&G), Intellectual Property (IP), Life Sciences - **Life Sciences Growth**: Strong demand in R&D, particularly for Cortellis product line [30][32] 6. Market Dynamics - **Healthcare Market**: Sustainable growth expected due to advancements in personalized medicine and AI integration [32][34] - **IP Segment**: Increased patent activity and AI-driven solutions like MacRisk and Derwent products [36][37] 7. Financial Performance and Margins - **EBITDA Margins**: Expected contraction to 41% due to disposals, with potential for recovery post-disposal [41][42] - **Margin Expansion**: Anticipated improvement as organic growth resumes, with a target of 2-3% growth leading to margin expansion [45] 8. Capital Allocation - **Balance Sheet Management**: Current gross leverage at 4.3 times; plans for debt paydown and share buybacks while maintaining flexibility [46] 9. Additional Insights - **Customer Engagement**: Focus on enhancing customer collaboration and engagement through innovative products [24][25] - **AI Cost Management**: Internal AI development is more economical compared to third-party vendors [17] Conclusion Clarivate is actively pursuing a transformation strategy focused on subscription models, product innovation, and enhancing sales execution, with a clear goal of driving organic revenue growth and improving shareholder value. The company is well-positioned to capitalize on market opportunities, particularly in the life sciences and IP sectors, while managing its financial health and capital allocation effectively.